Skip to main content

Acute impact of inhaled short acting b2-agonists on 5 km running performance

Dickinson, John W., Hu, Jiu, Chester, Neil, Loosemore, Mike, Whyte, Greg (2014) Acute impact of inhaled short acting b2-agonists on 5 km running performance. Journal of Sports Science & Medicine, 13 (2). pp. 271-279. ISSN 1303-2968. (KAR id:43896)

PDF Publisher pdf
Language: English
Download (539kB) Preview
[thumbnail of Dickinson et al 2014 Acute Impact of ISBA on 5 km running performance.pdf]
Preview
This file may not be suitable for users of assistive technology.
Request an accessible format
Official URL
https://www.jssm.org/volume13/iss2/cap/jssm-13-271...

Abstract

Whilst there appears to be no ergogenic effect from inhaled salbutamol no study has investigated the impact of the acute inhalation of 1600 µg, the World Anti-Doping Agency (WADA) daily upper limit, on endurance running performance. To investigate the ergogenic effect of an acute inhalation of short acting ?2-agonists at doses up to 1600 µg on 5 km time trial performance and resultant urine concentration. Seven male non-asthmatic runners (mean ± SD; age 22.4 ± 4.3 years; height 1.80 ± 0.07 m; body mass 76.6 ± 8.6 kg) provided written informed consent. Participants completed six 5 km time-trials on separate days (three at 18 °C and three at 30 °C). Fifteen minutes prior to the initiation of each 5 km time-trial participants inhaled: placebo (PLA), 800 µg salbutamol (SAL800) or 1600 µg salbutamol (SAL1600). During each 5 km time-trial HR, VO2, VCO2, VE, RPE and blood lactate were measured. Urine samples (90 ml) were collected between 30-180 minutes post 5 km time-trial and analysed for salbutamol concentration. There was no significant difference in total 5 km time between treatments (PLA 1714.7 ± 186.2 s; SAL800 1683.3 ± 179.7 s; SAL1600 1683.6 ± 190.7 s). Post 5 km time-trial salbutamol urine concentration between SAL800 (122.96 ± 69.22 ug·ml(-1)) and SAL1600 (574.06 ± 448.17 ug·ml(-1)) were not significantly different. There was no improvement in 5 km time-trial performance following the inhalation of up to 1600 µg of salbutamol in non-asthmatic athletes. This would suggest that the current WADA guidelines, which allow athletes to inhale up to 1600 µg per day, is sufficient to avoid pharmaceutical induced performance enhancement. Key pointsInhaling up to 1600 µg of Salbutamol does not result in improved 5 km time trial performance.The position of Salbutamol on the World Anti-Doping Agency list of prohibited appears justified.Athletes who use up to 1600 µg Salbutamol in one day need to review their therapy as it would suggest their respiratory condition is not under control.

Item Type: Article
Uncontrolled keywords: Anti-Doping; Asthma; Athlete care; Treatment; WADA code
Subjects: R Medicine > RC Internal medicine > RC1200 Sports medicine
Divisions: Divisions > Division of Natural Sciences > School of Sport and Exercise Sciences
Depositing User: John Dickinson
Date Deposited: 27 Nov 2014 12:44 UTC
Last Modified: 16 Feb 2021 12:56 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/43896 (The current URI for this page, for reference purposes)
Dickinson, John W.: https://orcid.org/0000-0002-1824-7402
  • Depositors only (login required):

Downloads

Downloads per month over past year